Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
September 06 2017 - 7:00AM
Business Wire
— ALKERMES INSPIRATION GRANTS® Program Will
Award up to $1 Million for the Development or Expansion
of Innovative Programs —
— Applications Now Open for Submission Through
Oct. 6, 2017 —
Alkermes plc (NASDAQ: ALKS) today announced that the company is
now accepting applications for the 2nd annual ALKERMES INSPIRATION
GRANTS® initiative. The competitive program will award up to $1
million in grants to organizations for implementation of
innovative, high-impact and replicable programs designed to make a
positive difference in the lives of people affected by mental
health and substance use disorders. The application period is now
open and will run through Oct. 6, 2017.
“We are facing an addiction and mental health crisis in the
U.S., and medicines are only one component of the comprehensive
care needed for the millions of people affected,” said Richard
Pops, Chief Executive Officer of Alkermes. “By funding innovative
organizations that are working on the front lines to provide
critical wraparound support services to help those most impacted,
we believe real and sustainable movement toward solutions is
possible.”
“Last year, more than 300 projects were submitted from 245
organizations across the country in just a few short weeks. We
never imagined such a response for a grants program in its first
year, but the volume of submissions quickly highlighted the need
for support is greater now than it has ever been,” stated Nikki
Levy, Vice President of Patient Engagement at Alkermes. “We awarded
15 grants in 2016 to programs demonstrating the potential for
high-impact, an ability to be replicated across the ecosystem
and/or inventive, and creative approaches to support the broader
needs of people in the mental health and addiction
communities.”
Alkermes will award up to $1 million in grants for the
development or expansion of programs to support mental health and
addiction communities in two key areas: improving or enhancing
support or resources for people affected by mental health concerns
or addiction and/or integrating the perspective of people affected
by mental health concerns or addiction into drug development or
care delivery. Eligible non-profit organizations may submit
applications for grants by clicking here or visiting
www.alkermes.com/responsibility/inspiration-grants. Multiple
submissions by the same organization are permitted.
Submissions are evaluated based on a set of standard criteria
and selected by Alkermes in partnership with an external panel from
the community.
“Initiatives like the ALKERMES INSPIRATION GRANTS program are
important to the mental health and addiction communities because
they prompt the development of critical services that have a direct
impact on people affected by these disorders. As one of the grant
recipients in 2016, we had the opportunity to develop a national,
accredited certification for National Certified Peer Specialists,”
said Patrick Hendry, Vice President of Peer Advocacy, Supports
& Services (PASS) at Mental Health America. “The ALKERMES
INSPIRATION GRANTS program has enabled us to increase the number of
peer support specialists who can offer a unique, lived experience
to build upon and enhance current treatment programs as well as
have an impact on those who are working toward achieving and
maintaining recovery.”
Only eligible U.S. 501(c)(3) non-profit organizations may apply.
These include, but are not limited to, patient organizations and
professional societies. The applications close at 11:59 p.m. on
Oct. 6, 2017. Grants will be awarded in November and funding will
be distributed at the end of the calendar year.
For more information on the ALKERMES INSPIRATION GRANTS program,
including the application, submission instructions and evaluation
criteria, please visit www.alkermes.com/inspirationgrants.
About AlkermesAlkermes plc is a fully integrated,
global biopharmaceutical company developing innovative medicines
for the treatment of central nervous system (CNS) diseases. The
company has a diversified commercial product portfolio and a
substantial clinical pipeline of product candidates for chronic
diseases that include schizophrenia, depression, addiction and
multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc
has an R&D center in Waltham, Massachusetts; a research and
manufacturing facility in Athlone, Ireland; and a manufacturing
facility in Wilmington, Ohio. For more information, please visit
Alkermes’ website at www.alkermes.com.
Note Regarding Forward-Looking StatementsCertain
statements set forth in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. The company
cautions that forward-looking statements are inherently uncertain.
Although the company believes that such statements are based on
reasonable assumptions within the bounds of its knowledge of its
business and operations, the forward-looking statements are neither
promises nor guarantees and they are necessarily subject to a high
degree of uncertainty and risk. Actual performance and results may
differ materially from those expressed or implied in the
forward-looking statements due to various risks and uncertainties.
These risks and uncertainties include, among others, those risks
and uncertainties described under the heading “Risk Factors” in the
company’s Annual Report on Form 10-K for the year ended Dec. 31,
2016 and Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2017 and June 30, 2017 and in subsequent filings made by
the company with the U.S. Securities and Exchange Commission (SEC),
which are available on the SEC’s website at www.sec.gov. Existing
and prospective investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. Except as required by law, the company disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release.
ALKERMES INSPIRATION GRANTS® is a registered trademark of
Alkermes, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170906005701/en/
Alkermes plcFor Investors:Eva Stroynowski,
+1-781-609-6823orSandy Coombs, +1-781-609-6377orFor Media:Lindsey
Smith, +1-781-609-6231
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Apr 2023 to Apr 2024